This is an aggregated industry headline. Read the full story at FierceBiotech →
Medtronic inks $650M deal for SPR Therapeutics
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product delivers short-term electrical nerve stimulation for chronic pain patients, for approximately $650 million in cash.
By FierceBiotech
· May 24, 2026
· via FierceBiotech
Image: FierceBiotech
Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
DealsBriefing
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
DealsPharmaceutical Technology ↗
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
DealsFiercePharma ↗
BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthrop…